BIOMEDICAL SCIENCES GRADUATE PROGRAM FALL 2012



Similar documents
Stem Cells and Inner Ear Cell Regeneration. Stefan Heller Stanford University School of Medicine

Stem Cell Quick Guide: Stem Cell Basics

STEM CELL FELLOWSHIP

The Effect of Myeloma Cells on Bone Metabolism is Heterogenous and Correlates with Underlying Genetic Lesions and Bone Disease In Vivo

guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research

Stem cells possess 2 main characteristics: Sources of pluripotent stem cells: -Long-term self renewal. -The inner cell mass of the blastocyst.

Support structure for genetic material

M The Nucleus M The Cytoskeleton M Cell Structure and Dynamics

5 Frequently Asked Questions About Adult Stem Cell Research

Demystifying Stem Cells. Brent Bost M.D., CPA, MBA, FACOG

How To Expand Hematopoietic Stem Cells

Discover the Possibilities Born With Your Baby

Biotechnology. Srivatsan Kidambi, Ph.D.

Wadsworth Center. New York State Department of Health. The New Faces BMS

LifeNet Health Presented by James Clagett, PhD., Chief Science Officer LifeNet Health - The Best Keep Secret in Regenerative Medicine

PT CordLife Indonesia Premium Cordblood Bank. PT CordLife Indonesia Premium Cordblood Bank

Stem Cell Research: Adult or Somatic Stem Cells

The Types of stem cells: Totipotent Pluripotent Multipotent

MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist

CURRICULUM VITAE. - Instructor, Department of Nutrition and Exercise Sciences, Oregon State University, Corvallis Oregon (

AAGPs TM Anti-Aging Glyco Peptides. Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule

Roche Position on Human Stem Cells

your complete stem cell bank

FORM ENTRY INSTRUCTIONS FOR THE RESEARCH SEMINARS AND EVENTS WEB PAGE

Basic Science in Medicine

Briefing on the second reading of the Human Fertilisation and Embryology Bill, Monday 19 November 2007.

Technology Breakthrough in Spinal Implants (Technical Insights)

Graduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine. Graduate Certificate. Metabolic & Nutritional Medicine

If you were diagnosed with cancer today, what would your chances of survival be?

Chapter 16 Reproductive Technology, Gene Therapy, and Stem Cells (modified)

The Therapeutic Potential of Human Umbilical Cord Blood Transplantation for Neonatal Hypoxic-Ischemic Brain Injury and Ischemic Stroke

A Local Stability of Mathematical Models for Cancer Treatment by Using Gene Therapy

Top Ten Things to Know About Stem Cell Treatments

FACULTY OF MEDICAL SCIENCE

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor

HUMAN STEM CELLS DERIVED FROM CORD BLOOD REDUCES THE SIZE OF PANCREATIC TUMOR IN SCID MICE.

[Indian Stem Cell Banking Market: Trends & Opportunities ( )]

Stem Cell-based Therapies and FDA Regulations

FGF-1 as Cosmetic Supplement

OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone.

Human stem cell research: a novel technology that will benefit patients Information and Position Paper

What we will discuss today

How To Treat Mesothelioma With A Tumor Stem Cell Inhibitor

A Genetic Analysis of Rheumatoid Arthritis

4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.

STEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE

Stem Cell Transplantation

INSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance

STEM CELL FACTS. The ISSCR is an independent, nonproft organization providing a global forum for stem cell research and regenerative medicine.

Uses of Flow Cytometry

X-Plain Vertebral Compression Fractures Reference Summary

J D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H

Do you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life

TECHNICAL INSIGHTS TECHNOLOGY ALERT

H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md

2019 Healthcare That Works for All

Your Monthly Miracle sm

5. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.

The ethics of stem cell research and treatment

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

15 Stem Cell Research

HemaCare Corporation Company Overview. Comprehensive Product and Service Solutions for BioResearch and Cellular Therapy

An Introduction to Stem Cells

What You Need to Know for Better Bone Health

CHARACTERISTIC FEATURES OF STEM CELLS. CLONING TECHNOLOGIES

Osteoporosis Medicines and Jaw Problems


Umbilical Cord Blood Stem Cells Current Status & Future Potential

It s not something you want to think about, but it s something you want to prepare for.

BIOMEDICAL ENGINEERING NEURO-ONCOLOGY

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities

Pseudohypoparathyroidism: A Variation on the Theme of Hypoparathyroidism

UC Davis Institute for Regenerative Cures A facility supported by the California Institute for Regenerative Medicine

Program Co-Chairmen: Dr. John Wagner, University of Minnesota Dr. Richard Champlin, M.D. Anderson Cancer Center

Holly E. Sikes Resuehr, Ph.D. CURRICULUM VITAE

Hormone Replacement Therapy : The New Debate. Susan T. Hingle, M.D.

PART I. SECTION 1. The legislature finds that an estimated. 128,000,000 Americans suffer from the crippling economic and

CURRICULUM VITAE DONNA C. HERMEY. Ph.D. (Anatomy and Cell Biology) June 1994 Temple University School of Medicine Philadelphia, PA

STEM CELLS : A THERAPEUTIC REVOLUTION JACQUES KADOCH ROBERT HEMMINGS MARINELA MANDRA

Human Health Sciences

BULLETIN. Slovak Republic Ministry of Health

Corporate Medical Policy

Patient Handbook on Stem Cell Therapies

SAVE A LIFE... BY GIVING LIFE!

12. November 2013 Jan Endell. From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma

Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases

Prostaglandin E2 Enhances Human Cord Blood Stem. Cell Xenotransplants and Shows Long-Term Safety. in Preclinical Nonhuman Primate Transplant Models

FINAL REPORT For Japan-Korea Joint Research Project AREA

Osseous Tissue & Structure. The skeletal system includes: Storage of minerals: calcium salts

PGY 206 ELEMENTARY PHYSIOLOGY. (3) An introductory survey course in basic human physiology. Prereq: One semester of college biology.

Transcription:

THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM FALL 2012 Reeva Aggarwal PhD Candidate MECHANISMS OF HUMAN CD34+ STEM CELL-MEDIATED REGULATION OF OSTEOPOROSIS IN A PRECLINICAL MODEL November 27 th, 2012 DHLRI, Room # 165 10:00 AM

VITA July, 1981............................ Born Chandigarh, India 2002................................ BS, Biophysics, Panjab University 2004................................ MS, Biophysics, Panjab University COMMITTEE MEMBERS Hiranmoy Das, PhD, Advisor Periannan Kuppusamy, PhD Sudha Agarwal, PhD Nancy L. Lill, PhD

ABSTRACT Osteoporosis is a systemic metabolic bone disease characterized by low mineral density and micro architectural deterioration of skeleton. Osteoporosis or porous bone disease can progress asymptomatic until bones fracture. It is a major cause of morbidity and medical expense worldwide. Lack of physical activity, hormonal disturbances, age, gender, hereditary and nutrition are some the factors implicated to cause this disease. Physiologically, bone is a dynamic organ that constantly undergoes remodeling. Bone consists of dense organic, inorganic and mineral components. At cellular level, balance/coupling between the activities of bone forming cells (osteoblasts) and bone resorbing cells (osteoclasts) maintains bone homeostasis. Increased bone loss due to increased osteoclast and decreased osteoblast activities is considered as an underlying cause of osteoporosis. Several therapies such as hormone replacement therapy in women, ingestion of anti-resorptives (bisphosphonates), implantation of osteoinductive device combined with change in lifestyle offers only temporary augmentation of bone mineral density with side effects. Since, cures for osteoporosis are limited, consequently the potential of stem cell based therapies is currently being considered. Adult stem cells, we used for this study express CD133+/CD34 surface marker, and are multipotent in nature, isolated from human umbilical cord blood, could be differentiated into many lineages depending upon the molecular cues received from their microenvironment. However, their limited numbers from a single unit restricts further experimental use of those cells. Thus, our lab developed a nanofiber-based expansion technology to obtain adequate numbers of CD34+ cells isolated for experimental use and potential therapeutic applications. Herein, we show that nanofiber-expanded CD34+ cells could be differentiated into osteoblastic lineage, in vitro. Systemically delivered CD34+ cells home to the bone marrow and significantly improve bone deposition, bone mineral density and bone micro-architecture in osteoporotic aged nonobese diabetic severe combined immunodeficient (NOD/SCID) mice. The elevated levels of osteocalcin, IL-10, GM-CSF, and decreased levels of MCP-1 in serum parallel the improvements in bone micro-architecture. Furthermore, CD34+ cells improved osteoblast activity and concurrently impaired osteoclast differentiation, maturation, and functionality. Mechanistically, CD34+ cells offer osteoprotection via the upregulation of osteoblastic factors such as Runtrelated transcription factor 2 (RUNX2) and its downstream effectors such as collagen type I alpha1 and osteocalcin. Consistent with our in vivo observations of impaired osteoclastic activities after CD34+ stem cell therapy, CD34+ cells have the ability to regulate nuclear translocation of osteoclastogenic differentiation factor called nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), and thus negatively regulating its downstream transcriptional activity, and osteoclastogenesis. Taken together, these findings demonstrate a novel approach for utilizing nanofiber-expanded CD34+ cells as a therapeutic application for the treatment of osteoporosis in a preclinical model.

RECENT ABSTRACTS AND PRESENTATION Human T Cells Limit Breast Tumor Growth Partly by Down Regulating Cell Survival-Related Molecules and Up Regulating Apoptosis-Related Molecules in Tumor Cells, AACR Annual Meeting; Chicago, IL, April 2012 Regulation of osteoblasts and osteoclasts by human umbilical cord blood derived CD34 stem cells in osteoporotic NOD/SCID mice. 9th Annual meeting of International Society for Stem Cell Research (ISSCR); Toronto, ON, Canada, June 2011 Preclinical Application of Hematopoietic Stem Cells for Osteoporosis; Finalist in Basic Biological Sciences Category, 25th Annual Edward Hayes Graduate Forum; OSU, Columbus, OH, February 2011 HSCs improve bone mineral density and bone remodelling in murine osteoporotic model. National Center for Regenerative Medicine (NCRM); Case Western Reserve University, Cleveland, OH. November 2010 Osteoblastic differentiation of hematopoietic stem cells for the treatment of osteoporosis. Annual DHLRI & OSUMC Research Day, Columbus, OH. October, 2009 AWARDS AND HONORS Finalist, March 2011. 25 th Edward F. Hayes Graduate Research Forum, OSU, Columbus, OH. Best Poster, November 2010. Annual Retreat of National Center for Regenerative Medicine (NCRM); Case Western Reserve University, Cleveland, OH.

RECENT PUBLICATIONS Original articles Aggarwal R, Lu J, Kanji S, Matthew J, Das M, Noble GJ, McMichael BK, Agarwal S, Hart RT, Sun Z, Lee BS, Rosol TJ, Jackson R, Mao HQ, Pompili VJ and Das H. Human Umbilical Cord Blood-Derived CD34+ Cells Reverse Osteoporosis in NOD/SCID Mice by Altering Osteoblastic and Osteoclastic Activities. PLoS One, 2012, 7(6): e39365. Aggarwal R, Lu J, Kanji S, Matthew J, Das M, Lustberg MB, Ray A, Pompili VJ, Shapiro CL, Das H. Human Vγ2Vδ2 T Cells Limit Breast Cancer Growth by Modulating Cell Survival- and Apoptosis-Related Molecules in Tumor Cells. Submitted Lu J, Aggarwal R, Kanji S, Matthew J, Das M, Pompili VJ and Das H. Human Ovarian Tumor cells Escape γδ T Cell Recognition Partly by Down Regulating Surface Expression of MICA and Limiting Cell Cycle Related Molecules, PLoS One, 2011, 6(9): e23348 Lu J, Kanji S, Aggarwal R, Das, M, Joseph M, Wu LC, Mao HQ, Pompili VJ, Hadjiconstantinou M, and Das H. Umbilical cord-derived hematopoietic stem cells improve dopaminergic neuron morphology in the MPTP-mice. Frontiers in Bioscience, 2012 -in press. Das, M, Lu J, Joseph M, Aggarwal R, Kanji S, McMichael B, Lee B, Agarwal S, Kuppusamy P, Pompili VJ, Jain M and Das H. Kruppel-like factor 2 (KLF2) Regulates Monocyte Differentiation and Functions in mbsa and IL-1β-Induced Arthritis. Current Molecular Medicine, 2012, 12(2), pp. 113-125. Review articles Aggarwal R, Lu J, Pompili VJ and Das H. Hematopoietic stem cells: transcriptional regulation, ex vivo expansion and clinical application. Current Molecular Medicine, 2012 Jan; 12(1): 34-49. (Invited Review, Peer-Reviewed). Aggarwal R, Pompili VJ, Das H. Genetic modification of ex-vivo expanded stem cells for clinical application. Frontiers in Bioscience. 2010 Jun 1; 15:854-71. (Invited Review, Peer- Reviewed). Lu J, Aggarwal R, Pompili VJ, Das H. A novel technology for hematopoietic stem cell expansion using combination of nanofiber and growth factors. Recent Patents on Nanotechnology. 2010 Jun; 4(2):125-35. (Invited Review, Peer-Reviewed).

Book chapters Aggarwal R, Pompili VJ and Das H. Hematopoietic stem cells and bone regeneration; In Stem Cells and Cancer Stem Cells, Volume 3, M. A. Hayat Ed. Springer 2012- in press. Aggarwal R, Pompili VJ and Das H. Hematopoietic stem cells in atherosclerotic development and resolution. In Chronic Inflammation: Molecular Pathophysiology, Nutritional and Therapeutic Interventions. S. Roy, D. Bagchi and S.P. Raychaudhuri Eds. CRC Press 2012: pp 77-89 (Chapter 6). ISBN: 978-1-43987-6. Lu J, Aggarwal R, Pompili VJ and Das H. Ex vivo expanded hematopoietic stem cells for ischemia, In Stem Cells and Cancer Stem Cells, Volume 2, M. A. Hayat Ed, Springer 2012: pp 219-229. ISBN: 978-94-007-2015-2. Aggarwal R, Lu J, Pompili VJ and Das H. Development of ischemic diseases and stem cell therapy. In Role of Natural Products and Bioactive Compounds in Disease Prevention. M.M. Essa, A. Manickavasagan and E. Sukumar Ed, Nova Science Publishers 2012: pp 71-89 (Chapter 4). ISBN: 978-1-62100-153-9.

Biomedical Sciences Graduate Program 1170 Graves Hall 333 W. 10 th Avenue Columbus, Ohio 43210 www.ibgp.org